» Articles » PMID: 28736180

Retreatment With Osimertinib Following Pneumonitis

Overview
Publisher Elsevier
Date 2017 Jul 25
PMID 28736180
Citations 14
Authors
Affiliations
Soon will be listed here.
Citing Articles

Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series.

Shimbu K, Hisakane K, Kadoma N, Nishima S, Atsumi K, Seike M Onco Targets Ther. 2024; 17:717-726.

PMID: 39234190 PMC: 11371895. DOI: 10.2147/OTT.S475836.


Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis.

Ito T, Tsuchiya K, Mori R, Akashi T, Oyama Y, Ikeda M Respir Med Case Rep. 2024; 49:102029.

PMID: 38712314 PMC: 11070756. DOI: 10.1016/j.rmcr.2024.102029.


Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).

Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S Target Oncol. 2024; 19(3):423-433.

PMID: 38613731 PMC: 11111546. DOI: 10.1007/s11523-024-01048-x.


Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.

Ikeo S, Yasuda N, Sakai Y, Hayashi Y, Sokai A, Iwata T Thorac Cancer. 2023; 14(10):958-960.

PMID: 36810936 PMC: 10067352. DOI: 10.1111/1759-7714.14831.


[Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report].

Gu J, Bai F, Song L, Wang Y Zhongguo Fei Ai Za Zhi. 2021; 24(11):804-807.

PMID: 34802213 PMC: 8607285. DOI: 10.3779/j.issn.1009-3419.2021.102.39.